© Reuters. FILE PHOTO: The Regeneron Pharmaceuticals company logo is seen on a building at the company’s Westchester campus in Tarrytown, New York, U.S. September 17, 2020. REUTERS/Brendan McDermid
(Reuters) -Regeneron Pharmaceuticals Inc said on Tuesday prior analyses suggested its COVID-19 antibody cocktail, and similar drugs, could have reduced activity against the Omicron coronavirus variant.
The drugmaker said analysis shows the individual mutations present in the Omicron variant indicate “that there may be reduced neutralization activity of both vaccine-induced and monoclonal antibody conveyed immunity”.
Further analyses are ongoing, the company said, adding that there was no direct data testing Omicron’s resistance to immunity gained from vaccines and monoclonal antibodies.
The comments follow Moderna (NASDAQ:) Inc’s chief executive officer, who said COVID-19 vaccines are unlikely to be as effective against the Omicron variant as they have been previously.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment